Bernat Olle, Vedanta Biosciences CEO
April 25, 2023 06:45 AM EDTUpdated 01:31 PM
Financing
Startups

Pfiz­er-backed Vedan­ta Bio­sciences lands $106M for PhI­II in C. diff, PhII in IBD

Kyle LaHucik

Senior Reporter

Vedan­ta Bio­sciences has se­cured the cash it needs to run a Phase III in Clostrid­ioides dif­fi­cile and a mid-stage tri­al in ul­cer­a­tive col­i­tis, with run­way …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times